Work

A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e15059

Authors: Richard Charles Curry, Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, John L. Villano, Carolyn Muller, Trisha Michel Wise-Draper, Anne M. Noonan, Vinay K. Puduvalli, Gilles Tapolsky, Ray Takigiku

Institutions: University of Cincinnati, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Montefiore Medical Center, University of Kentucky, University of New Mexico, The Ohio State University, The Ohio State University Wexner Medical Center, Bexion Pharmaceuticals (United States)

Language: English

Topic: Sphingolipid Metabolism and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286298008

Cites:

Cited by:

Related to: 10